Gülnür Görgün
Alper Alp
Mehmet Görgün
Hüseyin Elbi
Erdem Göker
Abstract
Multiple myeloma is the neoplastic proliferation of monoclonal plasma cells, usually bone marrow originated. It may cause various organ dysfunctions. It is not so rare to detect secondary malignancies associated with MM but this co-existence between MM and gastric cancer has been not very frequently reported. Secondary malignancy risk should be kept in mind during the follow-up of patients with MM
Sirohi B, Powles R. Multiple Myeloma. Lancet, 2004; 363: 875-87.
Smith A, Wisloff F, Samson D, UK Myeloma Forum, Nordic Myeloma Study Group, British Committee for Standards in Haematology. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol, 2006; 132: 410-51.
Dong C, Hemminki K. Second primary neoplasms among 53159 haematolymphoproliferative malignancy patients in Sweden, 1958– 1996: a search for common mechanisms. British Journal of Cancer 2001; 85: 997-1005.
Demir C, Atmaca M, Tasdemir E, Efe S. Association of multiple myeloma and gastric adenocarcinoma. Journal of Clinical and Experimental Investigations 2011; 2: 110-3.
Razavi P, Rand KA, Cozen W, Chanan-Khan A, Usmani S, Ailawadhi S. Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics. Blood Cancer Journal, 2013; 3: e121.
Kyle RA. Long-term survival in multiple myeloma. N Engl J Med, 1983; 308: 314-6.
Spedini P, Marchetti G, Morandi S. Gastric localization of multiple myeloma. Haematologica, 2001; 86: 223.
Grudeva-Popova J, Nenova I, Spasova M, Yaneva M, Beleva E, Аnanoshtev N. Multiple myeloma in association with second malignancy. JBUON 2013; 18: 448-52.
Cui Y, Liu T, Zhou Y, Ji Y, Hou Y, Jin W, et al. Five Cases Report of Solid Tumor Synchronously with Hematologic Malignancy. Cancer Res Treat, 2012; 44: 63-8.
MULTİPLE MYELOMLU YAŞLI HASTADA PLAZMASİTOMU TAKLİT EDEN MİDE ADENOKARSİNOMU
Sirohi B, Powles R. Multiple Myeloma. Lancet, 2004; 363: 875-87.
Smith A, Wisloff F, Samson D, UK Myeloma Forum, Nordic Myeloma Study Group, British Committee for Standards in Haematology. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol, 2006; 132: 410-51.
Dong C, Hemminki K. Second primary neoplasms among 53159 haematolymphoproliferative malignancy patients in Sweden, 1958– 1996: a search for common mechanisms. British Journal of Cancer 2001; 85: 997-1005.
Demir C, Atmaca M, Tasdemir E, Efe S. Association of multiple myeloma and gastric adenocarcinoma. Journal of Clinical and Experimental Investigations 2011; 2: 110-3.
Razavi P, Rand KA, Cozen W, Chanan-Khan A, Usmani S, Ailawadhi S. Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics. Blood Cancer Journal, 2013; 3: e121.
Kyle RA. Long-term survival in multiple myeloma. N Engl J Med, 1983; 308: 314-6.
Spedini P, Marchetti G, Morandi S. Gastric localization of multiple myeloma. Haematologica, 2001; 86: 223.
Grudeva-Popova J, Nenova I, Spasova M, Yaneva M, Beleva E, Аnanoshtev N. Multiple myeloma in association with second malignancy. JBUON 2013; 18: 448-52.
Cui Y, Liu T, Zhou Y, Ji Y, Hou Y, Jin W, et al. Five Cases Report of Solid Tumor Synchronously with Hematologic Malignancy. Cancer Res Treat, 2012; 44: 63-8.
There are 9 citations in total.
Details
Primary Language
Turkish
Journal Section
Case Report
Authors
Gülnür Görgün
Alper Alp
Van Bölge Eğitim ve Araştırma Hastanesi, Nefroloji, Van, Türkiye
Mehmet Görgün
Tepecik Eğitim ve Araştırma Hastanesi, Genel Cerrahi, İzmir, Türkiye
Hüseyin Elbi
Celal Bayar Üniversitesi Tıp Fakültesi, Aile Hekimliği, Manisa, Türkiye
Erdem Göker
Ege Üniversitesi Tıp Fakültesi, Tıbbi Onkoloji, İzmir, Türkiye
Görgün G, Alp A, Görgün M, Elbi H, Göker E (September 1, 2016) MULTİPLE MYELOMLU YAŞLI HASTADA PLAZMASİTOMU TAKLİT EDEN MİDE ADENOKARSİNOMU. Acıbadem Üniversitesi Sağlık Bilimleri Dergisi 3 178–181.